ArriVent to spotlight late-breaking Phase 1 ARR-217 data at ESMO 2026, with an October 26 webinar slated
Market Chameleon (Mon, 26-Oct 11:01 AM)
AVBP Rises After Cancer Cell Publication Highlights Firmonertinib’s Response and PFS in EGFR PACC-Mutant NSCLC
Market Chameleon (Mon, 19-Oct 11:57 AM)
AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg
Market Chameleon (Tue, 6-Oct 9:03 AM)
